RJFSA
VYGR icon

Raymond James Financial Services Advisors’s Voyager Therapeutics VYGR Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$177K Buy
30,213
+1,046
+4% +$7.61K ﹤0.01% 3216
2024
Q2 		$231K Buy
29,167
+731
+3% +$6.13K ﹤0.01% 3035
2024
Q1 		$265K Sell
28,436
-366
-1% -$3.09K ﹤0.01% 2922
2023
Q4 		$243K Sell
28,802
-1,775
-6% -$12.9K ﹤0.01% 2874
2023
Q3 		$237K Sell
30,577
-500
-2% -$4.57K ﹤0.01% 2817
2023
Q2 		$356K Sell
31,077
-175
-0.6% -$1.81K ﹤0.01% 2554
2023
Q1 		$241K Sell
31,252
-5,348
-15% -$42.5K ﹤0.01% 2780
2022
Q4 		$223K Sell
36,600
-1,188
-3% -$6.75K ﹤0.01% 2799
2022
Q3 		$224K Buy
37,788
+3,933
+12% +$25.2K ﹤0.01% 2778
2022
Q2 		$200K Sell
33,855
-1,589
-4% -$10.7K ﹤0.01% 2871
2022
Q1 		$270K Sell
35,444
-8,859
-20% -$39.5K ﹤0.01% 2794
2021
Q4 		$120K Sell
44,303
-23,212
-34% -$79.2K ﹤0.01% 3094
2021
Q3 		$178K Sell
67,515
-3,402
-5% -$11.1K ﹤0.01% 3017
2021
Q2 		$293K Sell
70,917
-5,301
-7% -$24K ﹤0.01% 2741
2021
Q1 		$359K Sell
76,218
-30,038
-28% -$205K ﹤0.01% 2511
2020
Q4 		$760K Sell
106,256
-81,596
-43% -$784K ﹤0.01% 1885
2020
Q3 		$2M Sell
187,852
-15,747
-8% -$185K 0.01% 1174
2020
Q2 		$2.57M Buy
203,599
+8,733
+4% +$102K 0.01% 1001
2020
Q1 		$1.78M Buy
194,866
+38,148
+24% +$438K 0.01% 940
2019
Q4 		$2.19M Sell
156,718
-39,813
-20% -$579K 0.01% 1123
2019
Q3 		$3.38M Sell
196,531
-11,346
-5% -$238K 0.01% 851
2019
Q2 		$5.66M Buy
207,877
+5,195
+3% +$119K 0.02% 632
2019
Q1 		$3.88M Buy
202,682
+19,481
+11% +$254K 0.02% 753
2018
Q4 		$1.72M Buy
183,201
+3,930
+2% +$50.4K 0.01% 991
2018
Q3 		$3.39M Buy
179,271
+732
+0.4% +$14K 0.02% 803
2018
Q2 		$3.49M Buy
178,539
+33,570
+23% +$663K 0.02% 755
2018
Q1 		$2.72M Buy
+144,969
New +$3.13M 0.02% 803
2017
Q4 		– Sell
-54,488
Closed -$1.12M – 2717
2017
Q3 		$1.12M Buy
+54,488
New +$615K 0.01% 1238

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raymond James Financial Services Advisors's VYGR Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Voyager Therapeutics (VYGR) stake by 3.6% in Q3 2024, buying an estimated $7.61K and bringing the position to 30,213 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

Raymond James Financial Services Advisors first reported a position in VYGR in Q3 2017 and has held it in 28 quarters since. The position peaked at $5.66M in Q2 2019. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Raymond James Financial Services Advisors held 30,213 shares of Voyager Therapeutics worth $177K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 1,046 Voyager Therapeutics shares in Q3 2024, an estimated $7.61K.
  • Voyager Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3216 holding.
  • Raymond James Financial Services Advisors first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 28 quarters since.
  • Raymond James Financial Services Advisors's Voyager Therapeutics position peaked at $5.66M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.